Gilead Sciences

BIDMC researchers develop decision-making tool to benefit patients with HCV

An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention. It …

University of Chicago

Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia

<b>– Recognized for Services to Medical Research –</b><p>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John …

Victorian Era

Gilead's Hot Stock May Cool Fast

Gilead Sciences, Inc. ( GILD) has been on a roll recently with shares rising by over 10% since May 7, easily outpacing the sector's rise of 7.5%, as …

Investing

Atara Biotherapeutics appoints Utpal Koppikar as Chief Financial Officer

Atara Biotherapeutics (NASDAQ:ATRA) announces that Utpal Koppikar has joined Atara as Chief Financial Officer, effective immediately.<p>Most recently, …

Business

2 Cheap Dividend Stocks You Can Buy Right Now

These two drug stocks have a lot to offer income investors and value investors.<p>Pay less to get paid more. That's exactly what can happen when you buy …

Investing

Gilead unit strikes out in bid to invalidate Juno cancer treatment patent | Reuters

A unit of Gilead Sciences Inc on Wednesday lost a bid to invalidate a patent on a novel cancer treatment owned by the Memorial Sloan Kettering Cancer Center in New York City.<p>The U.S. Court of Appeals for the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board that Gilead’s …

Law

New Ebola Outbreak May Open Door to Finding Drugs That Work

As another outbreak of Ebola claims lives in central Africa, researchers are seeing within it a rare ray of hope: a chance to find a cure. For the …

Disease

Gilead up 1% on reported settlement with Mylan over Tybost

Gilead Sciences (GILD +1.4%) perks up on below-average volume in apparent response to chatter that it is nearing a settlement with Mylan NV (MYL …

Gilead Sciences

3 Reasons Gilead Sciences Is a Better Value Stock Than Amgen

Amgen looks like a pretty good bargain right now, but Gilead stock is dirt cheap.<p>It's not too hard to find biotech stocks that are bargains right …

Amgen

Gilead Sciences Leads Its First Step Toward Pipeline Recovery With Clinical Candidate Filgotinib

Recently, <b>Gilead</b> (GILD) and its partner <b>Galapagos NV</b> (GLPG) announced successful data from a phase 2 study treating patients with psoriatic arthritis. …

Business

Bayside Academy Receives $200K STEM Grant

The grant came from Gilead Sciences, Inc., a biopharmaceutical company based in Foster City.<p>SAN MATEO, CA — San Mateo-Foster City School District …

San Mateo

Has the Gilead Sciences Buy Argument Collapsed?

Let's find out.<p>Long-time <b>Gilead Sciences</b> (NASDAQ:GILD) shareholders (like yours truly) have been on quite the rollercoaster ride. The company has seen …

Investing

2018 ASCO Conference Roundup

All your Motley Fool coverage of the 2018 ASCO Conference in one place.<p>The annual American Society of Clinical Oncology Conference kicks off Friday, …

American Society of Clinical Oncology

Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report?

1 / 2<p>Why Is Fidelity National (FIS) Up 2.7% Since Its Last Earnings Report?<p>Fidelity National (FIS) reported earnings 30 days ago. What's next for the …

Gilead Sciences

Why Amgen Revised Its Revenue Guidance for 2018

In its first-quarter conference call, Amgen (AMGN) revised its revenue guidance from $21.8 billion–$22.8 billion to $21.9 billion–$22.8 billion. …

Amgen

Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13

FOSTER CITY, Calif.--(BUSINESS WIRE)--<p>Gilead Sciences, Inc. (GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President and …

Goldman Sachs

[$$] Drugmakers struggle to find immunotherapy combinations for cancer

After decades of frustratingly slow progress in discovering new drugs to battle cancer, the breakthroughs have started to come thick and fast. …

Cancer

Kronos Bio inks $18 mln seed

New York City and Cambridge, Massachusetts-based <b>Kronos Bio Inc,</b> a developer of “first-in-class therapies against historically intractable targets,” …

Investing

Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6

FOSTER CITY, Calif.--(BUSINESS WIRE)--<p>Gilead Sciences, Inc. (GILD) today announced that John F. Milligan, PhD, Gilead’s President and Chief Executive …

Biotechnology

Gilead Sciences in €9.5m expansion of Cork plant

Biopharma giant Gilead Sciences has opened a new €9.5m facility at its plant in Cork.The Cork plant – which produces drugs for the treatment of HIV …

Biotechnology

Edge Wealth Management Has Cut Gilead Sciences (GILD) Stake; CANNABIX TECHNOLOGIES ORDINARY SHAR (BLOZF) Shorts Raised By 16.5%

<b>May 18, 2018 - By Linda Rogers</b><p>CANNABIX TECHNOLOGIES INC ORDINARY SHAR (OTCMKTS:BLOZF) had an increase of 16.5% in short interest. BLOZF’s SI was …

Biotechnology

3 High-Yield Stocks With Virtual Monopolies

This trio of high-yield stocks offers dividend investors a lock on key markets with virtual monopolies driving big dividend payments.<p>Not many …

Investing

Taking Stock of Gilead Sciences’ Key Developments

During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand …

Biotechnology

A Look at Gilead Sciences’ Competitive Scenario

Gilead Sciences’ (GILD) Viread sales decreased 63% from $260 million in Q1 2017 to $97 million in Q1 2018. Epclusa sales, which accounted for 12% of …

Biotechnology

Gilead Sciences Stock: How Much Upside Do Analysts Expect?

Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines …

Biotechnology

Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018

In the first quarter, Gilead Sciences’ (GILD) total product sales decreased to $5 billion from $6.3 billion in the first quarter of 2017. For fiscal …

Biotechnology

Kite Pharma continues buildout for cell therapy manufacture

Gilead Sciences' (NASDAQ:GILD) Kite Pharma has leased a 177K square-foot facility in the Netherlands for manufacturing cell therapies in Europe. The …

Business

Gilead Sciences: Resist Sentiment, Stop Speculating And Invest

After a few months of rather positive signs and slight increase in bullishness, bearish sentiment seems to be back. In 2016 and 2017 Wall Street …

Biotechnology

FDA OKs expanded use for Gilead's Truvada

The FDA approves the use of Gilead Sciences' (GILD -0.4%) Truvada (emtricitabine/TDF), in combination with safer sex practices, to reduce the risk of …

Biotechnology

vTv Therapeutics beats by $0.06, misses on revenue

vTv Therapeutics (NASDAQ:VTVT): Q1 EPS of -$0.30 beats by $0.06.<p>Revenue of $2.06M (+6766.7% Y/Y) misses by $0.27M.<p>Shares +0.62%.<p>Press Release<p>Now …

Biotechnology